Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 8/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 6/20 | 0.53 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674769 | 0.85 | HINT1 (0.72) | HINT1NT5EPNPKRASGSK3A | |
| SCHEMBL2675383 | 0.85 | HINT1 (0.72) | HINT1NT5EPNPKRASGSK3A | |
| SCHEMBL10001265 | 0.85 | HINT1 (0.72) | HINT1NT5EPNPKRASGSK3A | |
| SCHEMBL21350963 | 0.82 | HPGD (0.62) | HINT1NT5EPNPGSK3ARPS6KA3 | |
| SCHEMBL16569029 | 0.82 | HPGD (0.62) | HINT1NT5EPNPGSK3ARPS6KA3 | |
| SCHEMBL23813666 | 0.82 | HPGD (0.62) | HINT1NT5EPNPGSK3ARPS6KA3 | |
| SCHEMBL16569039 | 0.82 | HPGD (0.62) | HINT1NT5EPNPGSK3ARPS6KA3 | |
| SCHEMBL2680046 | 0.81 | HINT1 (0.61) | HINT1NT5EPNPKRASGSK3A | |
| SCHEMBL2675390 | 0.80 | HINT1 (0.71) | HINT1NT5EPNPKRASGSK3A | |
| SCHEMBL27575151 | 0.80 | HINT1 (0.74) | HINT1NT5EPNPKRASGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538100-A2 | COMBINATION OF A BRD4 INHIBITOR AND AN ANTIFOLATE FOR THE THERAPY OF CANCER | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2019-09-18 | — | — | EP | disclosed |
| US-20190262355-A1 | COMBINATION OF A BRD4 INHIBITOR AND AN ANTIFOLATE FOR THE THERAPY OF CANCER | CEMM-FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2019-08-29 | — | — | US | disclosed |
| WO-2018087401-A2 | COMBINATION OF A BRD4 INHIBITOR AND AN ANTIFOLATE FOR THE THERAPY OF CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262355-A1 | COMBINATION OF A BRD4 INHIBITOR AND AN ANTIFOLATE FOR THE THERAPY OF CANCER | BRD4, MTHFD1, BICRA | HINT1 2414/4885NT5E 2662/4885PNP 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.